First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer

This study is a Phase 1 clinical trial testing an oral investigational drug called SNV1521 together with a RAS-targeted cancer medicine in people with pancreatic cancer that cannot be removed by surgery or has spread. The main goals are to find doses of the drug combination that are safe and tolerable and to look for early signs that the treatment may help control the cancer. Participants will receive the study medicines in repeating cycles and will have regular blood tests, scans, and other exams to monitor side effects and how their cancer responds.

NCT Number	NCT07756281
Lead Sponsor	Synnovation Therapeutics, Inc. Collaborators: Revolution Medicines, Inc.
Conditions	Pancreatic Cancer, Pancreatic Acinar Carcinoma
Enrollment	40 participants
Start Date	2026-09
Primary Completion	2029-06-01 (estimated)
Study Completion	2029-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-10